drugset / Trial / NCT01260948
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
RandomizedCrossoverOpen-label
Summary
This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under non-fasting conditions.
Timeline
- Start
- 2006-04
- Primary completion
- 2006-05
- Completion
- 2006-05
Outcome
Met primary endpoint
registry Ratio of the T/R geometric mean x 100 98.72 (90% CI 94.13 to 103.53) NCT01260948 ↗
registry Ratio of the T/R geometric mean x 100 94.81 (90% CI 91.30 to 98.47) NCT01260948 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 10 mg | Oral |
Indications
No indication recorded.